Managing Vascular Dementia Risk Factors With SymTrend

Status Not yet recruiting

Clinical Trial Summary

Individuals with uncontrolled vascular disease are at risk for an insidious progression of brain injury starting in early to midlife and ultimately culminating in a vascular dementia, robbing them of activities of daily living independence. Successful containment of this progression requires rigorous vascular risk factor management - the control of blood pressure, blood sugars, weight, and alcohol consumption; the cessation of smoking, and an increase in aerobic activity. SymTrend's mobile and web system for managing vascular risk factors will help improve adherence to health and lifestyle strategies, will stem cognitive decline, and will preserve independence in the community for older adults.

Clinical Trial Description

Neurologists from Massachusetts General Hospital will refer 10 adults with vascular mild cognitive impairment for participation in this project. The patients will be given Bluetooth devices appropriate for their condition and will be trained to use SymTrend and Apple Health software. They will use the software and devices for three months; will receive messages throughout from the system and/or a research coordinator about their progress, with encouragement and strategies to fully manage their symptoms; and their neurologist will be in communication with them about the progress charts and will adjust their care on the basis of this real-time data. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03702543
Study type	Interventional
Source	SymTrend Inc.
Contact	Minna Levine, Phd
Phone	16174917510
Email	symtrend@gmail.com
Status	Not yet recruiting
Phase	Phase 1
Start date	October 15, 2018
Completion date	October 14, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04567745` - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers	Phase 1
Recruiting	`NCT04109963` - Trial of Remote Ischemic Pre-conditioning in Vascular Cognitive Impairment	Phase 2
Recruiting	`NCT04335994` - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing	N/A
Not yet recruiting	`NCT06416371` - Retinal Vessel Leakage in Cerebral Small Vessel Disease
Completed	`NCT01761227` - Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia	Phase 2
Active, not recruiting	`NCT01208675` - The Swedish BioFINDER Study
Completed	`NCT00165763` - Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia	Phase 4
Completed	`NCT00621647` - Seroquel- Agitation Associated With Dementia	Phase 3
Recruiting	`NCT04095962` - Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia	N/A
Recruiting	`NCT03275363` - The University of Hong Kong Neurocognitive Disorder Cohort	N/A
Active, not recruiting	`NCT03804229` - Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia	Phase 3
Enrolling by invitation	`NCT03724136` - Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study	N/A
Completed	`NCT02453932` - Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia	Phase 3
Completed	`NCT00947531` - A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia	Phase 4
Enrolling by invitation	`NCT02147652` - Personalized Music Therapy and Agitation in Dementia	N/A
Recruiting	`NCT04114994` - Longitudinal Cognitive Assessment by BoCA
Recruiting	`NCT06034509` - Cognitive and Vascular Functioning Following TBI
Recruiting	`NCT05921266` - Urolithin A Supplementation in Middle-aged Adults With Obesity	N/A
Completed	`NCT01465360` - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center	N/A
Not yet recruiting	`NCT01466543` - Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity	Phase 2